COVID-19 and the cardiovascular system

[1]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[2]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[3]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[4]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[5]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[6]  Y. Li,et al.  Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection , 2017, Scientific Reports.

[7]  A. Badawi,et al.  Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis , 2016, International Journal of Infectious Diseases.

[8]  T. Alhogbani.  Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus , 2016, Annals of Saudi medicine.

[9]  A. Fujiki,et al.  Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. , 2013, Journal of Cardiology Cases.

[10]  Nigel M Hooper,et al.  ACE2: from vasopeptidase to SARS virus receptor , 2004, Trends in Pharmacological Sciences.

[11]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.